Atara Biotherapeutics Inc (ATRA): שווי כולל של נכסי החברה
Atara Biotherapeutics (ATRA) develops innovative cell therapies to combat oncology and sclerosis. The stock's price history reflects the dynamics of total assets, which amount to 28.97. The uniqueness of its technologies and European regulatory approval for its drug secure the company's status as a market leader. Meanwhile, the stability of the R&D center is maintained through the targeted hiring of regulatory experts and the retention of leading scientists.
פילוחי מדדים מקיפים ואנליטיקה עבור atarabio.com (ATRA)
The scale of Atara Biotherapeutics operations in developing complex allogeneic drugs determines the company's current financial asset value at 28.97. This metric, reverse-calculated via ROA, consolidates the value of all resources and liabilities, allowing investors to assess the capitalization efficiency of the Ebvallo technological advantage and the resilience of the business's material base amid high barriers to entry in the cell therapy niche.